UNSPSC 51312301: Bromazine or bromodiphenhydramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H20BrNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T032BI7727, chemically known as ethanamine, 2-((4-bromophenyl)phenylmethoxy)-n,n-dimethyl- but generally known as bromazine, which bears US NIH Compound Identifier 2444. Bromazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05908MIG.

UNSPSC 51312301 Bromazine or bromodiphenhydramine (Commodity) covers pharmaceutical products and active pharmaceutical ingredients that state and local governments procure for clinical, community health, and pharmacy benefit programs. Recent solicitations show this code applied to broader pharmaceutical and drug deactivation product categories, including naloxone, generic multi-source medications, and over-the-counter items distributed through state health agencies, county health departments, and multistate cooperative purchasing alliances. Issuing bodies span state health and human services commissions, county government health initiatives, and regional cooperative purchasing organizations like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Vendors must meet federal compliance requirements including cGMP and Drug Supply Chain Security Act (DSCSA) certification, E-Verify employment eligibility verification, drug-free workplace certification, and comprehensive insurance coverage (commercial general liability, workers' compensation, professional liability, and network security liability). Contracts typically run two years with renewal options and include performance penalties for late reporting or missed onboarding timelines.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, targeting direct contracting relationships outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration issued MMCAP RFP S1070000015802 on January 20, 2026, due March 26, 2026, for multiple generic pharmaceutical and OTC product contracts serving participating state and local government facilities across Minnesota and Oregon, with awarded products distributed through three authorized wholesalers and a two-year term beginning July 1, 2026. Pricing evaluation weighted price competitiveness at 75 percent and required submission of detailed product information including National Drug Codes and manufacturing locations.